Background: Cisplatin (CIS) is averse -neoplastic substitute pro the therapy of solid
tumors. Conversely, an extraordinary incidence of harsh ototoxicity is prevalant in
patients remedied by CIS. Dexamethasone (DX) is a synthetic steroid equivalent
expended for the treatment of distinctive inner ear diseases. Erythropoietin (ER) had
well-established erythropoietic function plus strong anti-inflammatory, antiapoptotic validity.
Purpose: The principle of this study was to assess the otoprotective effects of
dexamethasone (DX) and erythropoietin (ER) administration in the CIS- aggravated
ototoxicity in rats.
Methods: Thirty-five rats apportioned into: Control group, CIS group, CIS + DX
group received an intraperitoneal injection of dexamethasone before CIS for 3
consecutive days, CIS + ER group, received an intraperitoneal injection of ER
before CIS for 3 days and CIS + DX + ER group, cisplatin obtained and pretreated
with dexamethasone and erythropoietin |
